Best Peptides for Joint Health: Evidence-Based Rankings

Why Peptides Offer a Unique Advantage for Joint Health

Joint health is a growing concern for millions of people worldwide, from aging athletes to those managing chronic joint conditions. While conventional treatments—anti-inflammatory supplements, physical therapy, and pharmaceuticals—offer temporary relief, they often fall short of addressing the root mechanisms of joint degradation.

Peptides represent a fundamentally different approach. As short chains of amino acids, peptides function as signaling molecules that communicate directly with your body's cells. Unlike general supplements that provide raw materials, peptides send specific instructions that can reduce inflammation, protect cartilage, stimulate bone remodeling, and enhance joint stability at a biochemical level.

The advantage is precision. A peptide like GLP-1 doesn't just help you lose weight—it simultaneously reduces osteoarthritis pain through both weight-dependent and weight-independent anti-inflammatory pathways. VIP doesn't generically suppress inflammation; it specifically upregulates protective factors in synovial fluid and downregulates cartilage-degrading enzymes. This targeted mechanism makes peptides particularly effective for joint health compared to broader-acting supplements.

This ranking focuses exclusively on peptides with the strongest evidence base for joint health, separated by evidence tier to help you distinguish between established therapies and promising but less-proven options.

Ranking Peptides by Evidence Strength for Joint Health

1. GLP-1 (Glucagon-Like Peptide-1) — Evidence Tier 4

What It Is: GLP-1 is a natural hormone that regulates blood sugar and appetite. The pharmaceutical versions—semaglutide and tirzepatide—are GLP-1 receptor agonists that have become widely used for weight management and metabolic health.

Evidence Tier for Joint Health: GLP-1 receptor agonists represent the highest level of evidence for joint health interventions, supported by multiple randomized controlled trials (RCTs) and meta-analyses showing clinically meaningful improvements in osteoarthritis outcomes.

Key Findings:

• Pain reduction: Semaglutide 2.4 mg reduced WOMAC (Western Ontario and McMaster Universities Osteoarthritis) pain scores by a mean of 34–36 points versus 22 points for placebo in a 68-week RCT with 407 participants (Bliddal et al.). This represents a 55% greater pain reduction compared to placebo.
• Weight loss mechanism: Mean body weight loss with semaglutide was 15.2%, approximately 14.5 kg. Notably, pain improvements occurred through both weight loss-dependent mechanisms (reducing joint load) and weight loss-independent mechanisms (direct anti-inflammatory signaling).
• Functional improvement: Participants showed measurable improvements in joint function and mobility, not just subjective pain perception.

Dosing: 100–300 mcg once or twice daily via subcutaneous injection

Cost: $40–$120 per month

Best For: Individuals with obesity and osteoarthritis, particularly of the knee. GLP-1 is especially effective if you have metabolic dysfunction (elevated blood sugar, insulin resistance) alongside joint problems, as it addresses multiple health issues simultaneously. Those seeking the most evidence-backed peptide intervention should prioritize this option.

Notable Advantage: Unlike other peptides on this list, GLP-1 has FDA approval for weight management, which has accelerated clinical research into its joint health benefits. The evidence base is robust and growing.

2. VIP (Vasoactive Intestinal Peptide) — Evidence Tier 3

What It Is: VIP is a naturally occurring neuropeptide in your nervous and immune systems. It acts as a potent anti-inflammatory signaling molecule, particularly in joint tissues. Clinical VIP is synthesized for research and therapeutic use.

Evidence Tier for Joint Health: VIP shows probable efficacy through multiple human observational studies and ex vivo cellular research demonstrating anti-inflammatory and cartilage-protective effects. However, no human RCTs currently exist, limiting confidence compared to Tier 4 evidence.

Key Findings:

• Synovial fluid deficit in OA: Patients with osteoarthritis showed 30% lower VIP concentrations in synovial fluid (470.83 pg/mL) compared to healthy controls (659.70 pg/mL, p<0.001; n=50 OA patients). This suggests VIP deficiency may contribute to joint degeneration.
• Disease severity correlation: Both synovial and cartilage VIP levels negatively correlated with OA disease severity (Spearman's ρ=0.838–0.814, p<0.001), indicating that lower VIP associates with worse joint disease.
• Enzyme suppression: In human OA synovial fibroblasts, VIP reduced expression of cartilage-degrading enzymes (ADAMTS-4, -5, -7, and -12) and decreased COMP (cartilage oligomeric matrix protein) degradation following inflammatory stimulation. The protective effect was particularly pronounced in established degradation pathways.

Dosing: 50 mcg per nostril (100 mcg total) four times daily via nasal spray

Cost: $150–$400 per month

Best For: Those with osteoarthritis or rheumatoid arthritis seeking an anti-inflammatory approach that specifically targets cartilage protection. VIP is particularly suited for individuals who cannot tolerate weight loss medications or who have normal body weight but significant joint inflammation. The nasal delivery method offers non-injectable convenience.

Notable Consideration: While mechanistic evidence is strong, the lack of human RCTs means clinical efficacy is less certain than GLP-1. VIP works best as part of a comprehensive joint health strategy rather than as a standalone solution.

3. Tirzepatide (Tirzepatide [Mounjaro/Zepbound]) — Evidence Tier 3

What It Is: Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both GIP and GLP-1 signaling pathways. This dual action produces stronger metabolic effects than GLP-1 alone, with emerging evidence for superior osteoarthritis prevention.

Evidence Tier for Joint Health: Tirzepatide demonstrates probable efficacy for reducing osteoarthritis risk in people with obesity, supported by large observational studies but not yet by dedicated RCTs for joint health outcomes.

Key Findings:

• OA risk reduction: Anti-obesity medications (including tirzepatide) were associated with 27% lower osteoarthritis risk compared to non-users in a retrospective cohort of 112,000 individuals (HR=0.73, 95% CI 0.67–0.79, p<0.01).
• Superior to semaglutide: Among anti-obesity medications, tirzepatide showed significantly lower OA risk than semaglutide alone (HR=0.57, 95% CI 0.50–0.65, p<0.0001), suggesting the GIP component may provide additional joint-protective benefits beyond weight loss.

Dosing: 2.5 mg starting dose, titrated to 5 mg, 10 mg, or 15 mg once weekly via subcutaneous injection

Cost: $150–$1,300 per month (significant variation based on insurance coverage and pharmacy)

Best For: Individuals with obesity and osteoarthritis who may benefit from the dual GIP/GLP-1 mechanism. Tirzepatide appears particularly effective for prevention of new-onset OA rather than treatment of established joint disease, making it useful for high-risk individuals seeking proactive joint protection.

Notable Consideration: Tirzepatide is newer than semaglutide with a smaller evidence base for joint health specifically. However, early data suggests it may be superior, making it worth considering despite the higher cost and less-established track record.

4. Retatrutide (Retatrutide [LY3437943]) — Evidence Tier 3

What It Is: Retatrutide is a novel triple GIP/GLP-1/glucagon receptor agonist, representing the newest generation of metabolic peptides. It activates three receptor pathways simultaneously, producing the strongest metabolic effects of any peptide class to date.

Evidence Tier for Joint Health: Retatrutide shows promise for knee osteoarthritis based on trial design and related compound efficacy, but definitive human efficacy data are pending. Current evidence comes from trial designs and reviews rather than published results.

Key Findings:

• Active clinical trials: TRIUMPH-4 is a Phase 3 RCT specifically designed to evaluate retatrutide for knee osteoarthritis, with WOMAC pain subscale as the primary endpoint. Results from this trial are anticipated and will provide the first Tier 4 evidence for a triple agonist.
• Related compound success: The related compounds tirzepatide (GIP/GLP-1 dual) and semaglutide (GLP-1) have demonstrated symptomatic improvements in knee osteoarthritis within broader obesity trials, supporting the plausibility of retatrutide's benefits.

Dosing: 2 mg–12 mg once weekly via subcutaneous injection

Cost: $180–$520 per month

Best For: Early adopters who want access to the newest peptide technology and are comfortable with incomplete data. Those who have tried GLP-1 or tirzepatide without adequate joint improvement might benefit from retatrutide's triple mechanism. Best reserved for use under medical supervision as evidence accumulates.

Notable Consideration: This is a "watch closely" peptide. Once TRIUMPH-4 results are published, retatrutide may move to Tier 4 evidence and become the preferred option for many patients. For now, GLP-1 and tirzepatide remain safer bets with established efficacy.

5. Thymopentin (Thymopentin [TP-5]) — Evidence Tier 3

What It Is: Thymopentin is a synthetic peptide derived from thymosin, a hormone produced by the thymus gland. It modulates immune function by enhancing T-cell differentiation and function, which has immune-regulatory applications for inflammatory joint diseases.

Evidence Tier for Joint Health: Thymopentin shows probable efficacy based on three human RCTs and one observational study demonstrating improvements in pain and inflammatory markers in rheumatoid arthritis and degenerative joint disease. However, studies are small (n<50), conducted decades ago, and lack modern replication.

Key Findings:

• Symptom resolution: In degenerative joint disease, intra-articular thymopentin injection resulted in pain symptom disappearance in the majority of patients by two months post-treatment with no reported side effects (Zanasi et al.).
• Immune modulation: In rheumatoid arthritis synovial fluid, thymopentin increased CD8+CD11b+ T cells and suppressor-inducer/naive T cells with statistically significant correlation (Afeltra et al.). Clinical parameters improved significantly alongside these immune changes.

Dosing: 1 mg three times per week via intramuscular or intra-articular injection

Cost: $40–$120 per month

Best For: Those with rheumatoid arthritis or other autoimmune joint conditions, particularly if conventional immunosuppressive therapy is insufficient or poorly tolerated. The intra-articular injection option allows direct delivery to affected joints. Best used under medical supervision given the immune-modulating mechanism.

Notable Limitation: Evidence is dated and minimal by modern standards. While results are encouraging, the lack of contemporary replication means thymopentin should be considered a secondary option after more well-established peptides have been tried. Its narrow clinical window (rheumatoid arthritis rather than osteoarthritis) further limits general applicability.

6. Abaloparatide (Abaloparatide [Tymlos]) — Evidence Tier 3

What It Is: Abaloparatide is an anabolic peptide that stimulates bone-building osteoblasts. It's an FDA-approved medication for osteoporosis that works by accelerating bone remodeling and increasing bone mineral density.

Evidence Tier for Joint Health: Abaloparatide demonstrates probable efficacy for joint health through improved bone density in regions supporting joint stability (hip, acetabular regions), supported by multiple human RCTs. However, evidence is limited to bone health outcomes rather than direct effects on cartilage, joint function, or osteoarthritis symptom relief.

Key Findings:

• Acetabular bone density: Abaloparatide increased acetabular bone mineral density in all DeLee-Charnley zones by 7–10% at 18 months versus placebo in 500 postmenopausal women (ACTIVE trial, human RCT).
• Femur strength in men: In men with osteoporosis, abaloparatide significantly increased femur strength based on finite element analysis at 6 and 12 months, with gains primarily in trabecular bone (ATOM trial, human RCT).

Dosing: 80 mcg once daily via subcutaneous injection

Cost: $1,800–$2,800 per month

Best For: Older adults with both osteoporosis and osteoarthritis, particularly those concerned about fracture risk. The bone-strengthening effects may indirectly support joint stability, making this useful as a secondary intervention for joint health alongside treatments targeting cartilage and inflammation.

Notable Limitation: Abaloparatide's mechanism benefits bone but doesn't directly address cartilage protection or inflammation—the primary drivers of osteoarthritis pain. It's best viewed as a complementary therapy rather than a primary joint health intervention. The high cost further limits general use.

7. Orexin-A (Orexin-A [Hypocretin-1]) — Evidence Tier 3

What It Is: Orexin-A is a neuropeptide produced in the brain that regulates wakefulness, metabolism, and immune function. Beyond its classical sleep-wake roles, emerging evidence suggests it has cartilage-protective and anti-inflammatory properties relevant to joint health.

Evidence Tier for Joint Health: Orexin-A shows promise through laboratory and animal studies demonstrating cartilage protection and inflammation reduction, supported by one small human RCT. However, evidence in humans for joint health is limited and preliminary.

Key Findings:

• Pain reduction in humans: A multi-ingredient supplement containing orexin-A reduced Visual Analog Scale pain scores significantly (p<0.001) versus placebo in 25 physically active adults over 14 days (human RCT). Note: This was a combination product, so isolated orexin-A effects cannot be fully determined.
• Cartilage protection mechanism: Orexin-A prevented IL-1β-induced degradation of type II collagen and aggrecan in human primary chondrocytes, with reduced expression of cartilage-degrading enzymes (MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5; human in vitro study).

Dosing: 100–400 mcg once or twice daily via nasal spray

Cost: $80–$300 per month

Best For: Individuals with joint pain who also struggle with sleep quality or fatigue, as orexin-A may address multiple concerns simultaneously. The nasal delivery method provides non-injectable convenience.

Notable Limitation: The single human joint health RCT used a combination product, making it impossible to isolate orexin-A's individual contribution. Most evidence comes from laboratory studies rather than clinical trials. Orexin-A should be considered experimental for joint health purposes and reserved for use after more established peptides have been optimized.

8. Teriparatide (Teriparatide [Forteo]) — Evidence Tier 3

What It Is: Teriparatide is a synthetic version of parathyroid hormone (PTH 1-34). Like abaloparatide, it's an FDA-approved anabolic agent that stimulates bone remodeling, primarily used to treat osteoporosis and increase fracture resistance.

Evidence Tier for Joint Health: Teriparatide shows promise in animal models and mechanistic studies suggesting it may slow osteoarthritis progression and reduce pain. However, human efficacy for joint health remains largely unproven—published evidence focuses on bone density and fracture prevention in osteoporosis, not joint disease outcomes.

Key Findings:

• Animal OA progression: In vivo animal studies (n=22) showed that teriparatide slowed OA progression, alleviated cartilage degeneration, and promoted subchondral bone remodeling (systematic review).
• Weight-bearing and endurance: Rats with ACL-induced OA treated with intra-articular PTH 1-34 showed significantly improved weight-bearing and running endurance, preserved glycosaminoglycan and collagen II, reduced OARSI score (p<0.05), and reduced chondrocyte apoptosis via autophagy activation.

Dosing: 20 mcg once daily via subcutaneous injection

Cost: $800–$3,200 per month

Best For: Older adults with both osteoporosis and osteoarthritis who need bone-building therapy.